Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390263 | 0.91 | ALDH1A1 (0.59) | NPC1CYP2C9ABL1ALDH1A1LMNA | |
| SCHEMBL4279399 | 0.83 | HPGD (0.51) | NPC1CYP2C9ABL1ALDH1A1LMNA | |
| SCHEMBL11768573 | 0.81 | CHEK2 (0.41) | CYP2C9ABL1ALDH1A1LMNAHTT | |
| SCHEMBL1108963 | 0.81 | NPC1 (0.54) | NPC1CYP2C9ABL1ALDH1A1LMNA | |
| SCHEMBL8954685 | 0.79 | KDR (0.45) | NPC1CYP2C9ABL1ALDH1A1LMNA | |
| SCHEMBL11766590 | 0.77 | MAP2K1 (0.44) | NPC1CYP2C9ABL1ALDH1A1LMNA | |
| SCHEMBL11768642 | 0.77 | KMT2A (0.46) | NPC1ABL1ALDH1A1LMNAHPGD | |
| SCHEMBL11096785 | 0.77 | TDP1 (0.35) | ALDH1A1HTTMAPTNPSR1CHEK2 | |
| SCHEMBL21981201 | 0.77 | NPC1 (0.50) | NPC1CYP2C9ABL1ALDH1A1LMNA | |
| SCHEMBL4204424 | 0.77 | NPC1 (0.64) | NPC1CYP2C9ABL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-0024842-B1 | METHYL (5-(2-THIENYLHYDROXYMETHYL)-1H-BENZIMIDAZOL-2-YL) CARBAMATE, PROCESS FOR ITS PREPARATION AND COMPOSITIONS CONTAINING IT | SMITHKLINE BECKMAN CORPORATION (US) | 1983-10-05 | — | — | EP | claimed |
| US-20130101616-A1 | COMPOSITIONS OF BOTANICAL EXTRACTS FOR CANCER THERAPY | DAO JAMES (US) | 2013-04-25 | — | — | US | disclosed |
| US-8173177-B2 | From Ganoderma lucidum, Salvia miltiorrhiza, and Scutellaria barbata | GENYOUS BIOMED INTERNATIONAL INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20090264533-A1 | Methods and Compositions for Modulating RHO-Mediated Gene Transcription | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2009-10-22 | — | — | US | disclosed |
| EP-1663103-A4 | COMPOSITIONS OF BOTANICAL EXTRACTS FOR CANCER THERAPY | GENYOUS BIOMED INTERNAT INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| EP-1667528-A4 | HIPPOPHAE RHAMNOIDES COMPOSITIONS FOR CANCER THERAPY | GENYOUS BIOMED INTERNAT INC (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20030013703-A1 | Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization | LIAO JAMES K (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020143042-A1 | Method and composition for treating cancer using cellular organelle crystallizing agents | KONG QINGZHONG (US) | 2002-10-03 | — | — | US | disclosed |
| US-6423751-B1 | PROVIDED THE AGENT IS NOT A RHO GTPASE FUNCTION INHIBITOR; TREATING PULMONARY HYPERTENSION, ISCHEMIC STROKE, IMPOTENCE, HEART FAILURE, RENAL DISEASE, ESOPHAGEAL MOTILITY SYNDROME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2002-07-23 | — | — | US | disclosed |
| US-20020082281-A1 | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-06-27 | — | — | US | disclosed |
| US-6376525-B1 | Tetrazolium salts and derivatives, preferably tetrazolium red and tetrazolium violet, in combination with chemotherapeutic agents delivered in a polylactic acid carrier; noninvasive antitumor treatments | KONG QINGZHONG (US) | 2002-04-23 | — | — | US | disclosed |
| EP-1070140-A1 | COMPOSITIONS AND METHODS FOR TREATING CELLS HAVING DOUBLE MINUTE DNA | Newbiotics Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000003746-A2 | UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999035292-A1 | COMPOSITIONS AND METHODS FOR TREATING CELLS HAVING DOUBLE MINUTE DNA | NEWBIOTICS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| US-4533672-A | Amino, cyano phenylthio or phenoxyl indole derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264533-A1 | Methods and Compositions for Modulating RHO-Mediated Gene Transcription | RHOA, RHOXF2, CDC42 | NPC1 1366/4885CYP2C9 4852/4885ABL1 975/4885 |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | NPC1 4661/4885CYP2C9 4858/4885ABL1 2764/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | NPC1 4661/4885CYP2C9 4858/4885ABL1 2764/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | NPC1 335/4885CYP2C9 3845/4885ABL1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.